Zampilimab

Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2) . Zampilimab inhibits TG2 crosslinking transamidation activity with an IC50 of 0.25 nM and a Kd of [1][2][3].

Product Specifications

CAS Number

[2098280-42-1]

Product Name Alternative

UCB-7858

UNSPSC

12352203

Target

Glutaminase

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/zampilimab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Zampilimab]

Molecular Weight

(143.48 kDa)

References & Citations

[1]Tempest R, et al. The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment. Cancers (Basel) . 2021 Jun 3;13 (11) :2788.|[2]Prat-Duran J, et al. Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and pharmacological inhibition. Pharmacol Ther. 2021 Jun;222:107787. |[3]Huang L, et al. The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease. PLoS One. 2024 May 16;19 (5) :e0298864.